Trinity Capital (NASDAQ:TRIN – Get Free Report) and Dominari (NASDAQ:DOMH – Get Free Report) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Institutional & Insider Ownership
24.6% of Trinity Capital shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 4.3% of Trinity Capital shares are held by insiders. Comparatively, 55.3% of Dominari shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Trinity Capital and Dominari”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Trinity Capital | $216.31 million | 7.71 | $135.60 million | $1.75 | 10.07 |
| Dominari | $123.10 million | 0.48 | -$22.43 million | ($5.39) | -0.45 |
Trinity Capital has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Trinity Capital, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings for Trinity Capital and Dominari, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Trinity Capital | 1 | 1 | 4 | 1 | 2.71 |
| Dominari | 1 | 0 | 0 | 0 | 1.00 |
Trinity Capital currently has a consensus price target of $16.67, suggesting a potential downside of 5.38%. Given Trinity Capital’s stronger consensus rating and higher possible upside, research analysts clearly believe Trinity Capital is more favorable than Dominari.
Profitability
This table compares Trinity Capital and Dominari’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Trinity Capital | 43.45% | 14.94% | 6.69% |
| Dominari | -51.61% | -235.37% | -163.66% |
Risk & Volatility
Trinity Capital has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.
Summary
Trinity Capital beats Dominari on 12 of the 15 factors compared between the two stocks.
About Trinity Capital
Trinity Capital Inc. is a business development company. It is a venture capital firm specializing in venture debt to growth stage companies looking for loans and/or equipment financing. Trinity Capital Inc. was founded in 2019 is based in Phoenix, Arizona with additional offices in the United States.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Receive News & Ratings for Trinity Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Capital and related companies with MarketBeat.com's FREE daily email newsletter.
